Identification of candidate anti-cancer molecular mechanisms of compound kushen injection using functional genomics

Oncotarget

Volumn 7, Issue 40, 2016, Pages 66003-66019

  Qu, Zhipeng ^a   Cui, Jian ^a   Harata Lee, Yuka ^a   Aung, Thazin Nwe ^a   Feng, Qianjin ^b   Raison, Joy M ^a   Kortschak, Robert Daniel ^a   Adelson, David L ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SHANXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

LncRNA; Systems biology; Traditional chinese medicine; Transcriptome

Indexed keywords

CASPASE 3; CASPASE 7; FLUOROURACIL; HERBACEOUS AGENT; KUSHEN; LONG UNTRANSLATED RNA; PROTEIN P53; TRANSCRIPTOME; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; FUNCTIONAL GENOMICS; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; BREAST TUMOR; CELL CYCLE; CHEMISTRY; CHINA; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CHINA; DRUGS, CHINESE HERBAL; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; RNA, LONG NONCODING; TUMOR CELLS, CULTURED;

EID: 84994180818     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11788     Document Type: Article

References (56)

1. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, et al. The genomic complexity of primary human prostate cancer. Nature. 2011; 470: 214-20. doi: 10.1038/nature09744.
2. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordonez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010; 463: 191-6. doi: 10.1038/nature08658.
3. Saadatpour A, Lai S, Guo G, Yuan GC. Single-Cell Analysis in Cancer Genomics. Trends Genet. 2015; 31: 576-86. doi: 10.1016/j.tig.2015.07.003.
4. Barrett CL, DeBoever C, Jepsen K, Saenz CC, Carson DA, Frazer KA. Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy. Proc Natl Acad Sci U S A. 2015; 112: E3050-7. doi: 10.1073/pnas.1508057112.
5. White NM, Cabanski CR, Silva-Fisher JM, Dang HX, Govindan R, Maher CA. Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biol. 2014; 15: 429. doi: 10.1186/s13059-014-0429-8.
6. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, Cao X, Jing X, Wang X, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011; 29: 742-9. doi: 10.1038/nbt.1914.
7. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov. 2013; 12: 358-69. doi: 10.1038/nrd3979.
8. Hsiao WL, Liu L. The role of traditional Chinese herbal medicines in cancer therapy from TCM theory to mechanistic insights. Planta Med. 2010; 76: 1118-31. doi: 10.1055/s-0030-1250186.
9. Sun M, Cao H, Sun L, Dong S, Bian Y, Han J, Zhang L, Ren S, Hu Y, Liu C, Xu L, Liu P. Antitumor activities of kushen: literature review. Evid Based Complement Alternat Med. 2012; 2012: 373219. doi: 10.1155/2012/373219.
10. Zhao Z, Fan H, Higgins T, Qi J, Haines D, Trivett A, Oppenheim JJ, Wei H, Li J, Lin H, Howard OM. Fufang Kushen injection inhibits sarcoma growth and tumorinduced hyperalgesia via TRPV1 signaling pathways. Cancer Lett. 2014; 355: 232-41. doi: 10.1016/j. canlet.2014.08.037.
11. Xu W, Lin H, Zhang Y, Chen X, Hua B, Hou W, Qi X, Pei Y, Zhu X, Zhao Z, Yang L. Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/beta-catenin pathway. J Exp Clin Cancer Res. 2011; 30: 103. doi: 10.1186/1756-9966-30-103.
12. Ma Y, Gao HM, Liu J, Chen LM, Zhang QW, Wang ZM. Identification and Determination of the Chemical Constituents in a Herbal Preparation, Compound Kushen Injection, by Hplc and Lc-Dad-Ms/Ms. Journal of Liquid Chromatography & Related Technologies. 2014; 37: 207-20 doi: 10.1080/10826076.2012.738623.
13. Yu P, Liu Q, Liu K, Yagasaki K, Wu E, Zhang G. Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling. Cytotechnology. 2009; 59: 219-29. doi: 10.1007/s10616-009-9225-9.
14. Liu T, Song Y, Chen H, Pan S, Sun X. Matrine inhibits proliferation and induces apoptosis of pancreatic cancer cells in vitro and in vivo. Biol Pharm Bull. 2010; 33: 1740-5. doi:
15. Chen H, Zhang J, Luo J, Lai F, Wang Z, Tong H, Lu D, Bu H, Zhang R, Lin S. Antiangiogenic effects of oxymatrine on pancreatic cancer by inhibition of the NF-kappaB-mediated VEGF signaling pathway. Oncol Rep. 2013; 30: 589-95. doi: 10.3892/or.2013.2529.
16. Ling Q, Xu X, Wei X, Wang W, Zhou B, Wang B, Zheng S. Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c. J Exp Clin Cancer Res. 2011; 30: 66. doi: 10.1186/1756-9966-30-66.
17. Zhang Y, Piao B, Zhang Y, Hua B, Hou W, Xu W, Qi X, Zhu X, Pei Y, Lin H. Oxymatrine diminishes the side population and inhibits the expression of beta-catenin in MCF-7 breast cancer cells. Med Oncol. 2011; 28: S99-107. doi: 10.1007/s12032-010-9721-y.
18. Guo YM, Huang YX, Shen HH, Sang XX, Ma X, Zhao YL, Xiao XH. Efficacy of Compound Kushen Injection in Relieving Cancer-Related Pain: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2015; 2015: 840742. doi: 10.1155/2015/840742.
19. Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim JS, Kim CJ, Kusanovic JP, Romero R. A novel signaling pathway impact analysis. Bioinformatics. 2009; 25: 75-82. doi: 10.1093/bioinformatics/btn577.
20. Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 2013; 14: 518-28. doi: 10.1038/nrm3629.
21. Schaarschmidt D, Ladenburger EM, Keller C, Knippers R. Human Mcm proteins at a replication origin during the G1 to S phase transition. Nucleic Acids Res. 2002; 30: 4176-85. doi:
22. Pellecchia A, Pescucci C, De Lorenzo E, Luceri C, Passaro N, Sica M, Notaro R, De Angioletti M. Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition. Oncogenesis. 2012; 1: e20. doi: 10.1038/oncsis.2012.20.
23. Cabili MN, Trapnell C, GoffL, Koziol M, Tazon-Vega B, Regev A, Rinn JL. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011; 25: 1915-27. doi: 10.1101/gad.17446611.
24. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012; 22: 1775-89. doi: 10.1101/gr.132159.111.
25. Lin KT, Shann YJ, Chau GY, Hsu CN, Huang CY. Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing. Oncogene. 2014; 33: 4786-94. doi: 10.1038/onc.2013.424.
26. Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, Gnad F, Guan Y, Gilbert HN, Stinson J, Klijn C, Guillory J, Bhatt D, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 2012; 22: 2315-27. doi: 10.1101/gr.140988.112.
27. Walsh AA, Szklarz GD, Scott EE. Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J Biol Chem. 2013; 288: 12932-43. doi: 10.1074/jbc. M113.452953.
28. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol. 2007; 47: 263-92 doi: 10.1146/annurev.pharmtox.47.120505.105337.
29. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993; 7: 812-21. doi:
30. Hibi K, Nakamura H, Hirai A, Fujikake Y, Kasai Y, Akiyama S, Ito K, Takagi H. Loss of H19 imprinting in esophageal cancer. Cancer Res. 1996; 56: 480-2. doi:
31. Adriaenssens E, Dumont L, Lottin S, Bolle D, Lepretre A, Delobelle A, Bouali F, Dugimont T, Coll J, Curgy JJ. H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression. Am J Pathol. 1998; 153: 1597-607. doi: 10.1016/S0002-9440(10)65748-3.
32. Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015; 21: 1253-61. doi: 10.1038/nm.3981.
33. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. Science. 2013; 339: 1546-58. doi: 10.1126/science.1235122.
34. Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, Degenhardt J, Mayba O, Gnad F, Liu J, Pau G, Reeder J, Cao Y, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol. 2015; 33: 306-12. doi: 10.1038/nbt.3080.
35. Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, Doroshow JH, et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 2013; 73: 4372-82. doi: 10.1158/0008-5472.CAN-12-3342.
36. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, Hashimoto-Tamaoki T. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 2001; 61: 1029-37. doi:
37. Hernandez-Vargas H, Ballestar E, Carmona-Saez P, von Kobbe C, Banon-Rodriguez I, Esteller M, Moreno-Bueno G, Palacios J. Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer. 2006; 119: 1164-75. doi: 10.1002/ijc.21938.
38. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014; 15: 49-63. doi: 10.1038/nrm3722.
39. Chang C, Liu SP, Fang CH, He RS, Wang Z, Zhu YQ, Jiang SW. Effects of matrine on the proliferation of HT29 human colon cancer cells and its antitumor mechanism. Oncol Lett. 2013; 6: 699-704. doi: 10.3892/ol.2013.1449.
40. Zhang Y, Zhang H, Yu P, Liu Q, Liu K, Duan H, Luan G, Yagasaki K, Zhang G. Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration. Cytotechnology. 2009; 59: 191-200. doi: 10.1007/s10616-009-9211-2.
41. Liu J, Yao Y, Ding H, Chen R. Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells. Tumour Biol. 2014; 35: 5409-15. doi: 10.1007/s13277-014-1705-7.
42. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012; 30: 679-92. doi: 10.1038/nbt.2284.
43. Garman KS, Nevins JR, Potti A. Genomic strategies for personalized cancer therapy. Hum Mol Genet. 2007; 16: R226-32. doi: 10.1093/hmg/ddm184.
44. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015; 14: 561-84. doi: 10.1038/nrd4591.
45. Petrelli A, Giordano S. From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem. 2008; 15: 422-32. doi:
46. Vanneman M, DranoffG. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012; 12: 237-51. doi: 10.1038/nrc3237.
47. Wang Y, Fan X, Qu H, Gao X, Cheng Y. Strategies and techniques for multi-component drug design from medicinal herbs and traditional Chinese medicine. Curr Top Med Chem. 2012; 12: 1356-62. doi:
48. Yang Y, Han L, Yuan Y, Li J, Hei N, Liang H. Gene co-expression network analysis reveals common system-level properties of prognostic genes across cancer types. Nat Commun. 2014; 5: 3231. doi: 10.1038/ncomms4231.
49. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006; 1: 1458-61. doi: 10.1038/nprot.2006.238.
50. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013; 29: 15-21. doi: 10.1093/bioinformatics/bts635.
51. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010; 26: 139-40. doi: 10.1093/bioinformatics/btp616.
52. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pages F, Trajanoski Z, Galon J. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009; 25: 1091-3. doi: 10.1093/bioinformatics/btp101.
53. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13: 2498-504. doi: 10.1101/gr.1239303.
54. Luo W, Brouwer C. Pathview: an R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics. 2013; 29: 1830-1. doi: 10.1093/bioinformatics/btt285.
55. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008; 9: 559. doi: 10.1186/1471-2105-9-559.
56. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4: 44-57. doi: 10.1038/nprot.2008.211.